Nail Psoriasis: A Review Article | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 257, Volume 89, Issue 2, October 2022, Page 7814-7817 PDF (408.95 K) | ||||
| DOI: 10.21608/ejhm.2022.277154 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
| Amany Abdel El Rahman Nassar; Fathia Mohamed Khattab; Aya Hassan Abdelfattah Abdallah* | ||||
| Dermatology, Venereology and Andrology, Faculty of Medicine – Zagazig University, Egypt | ||||
| Abstract | ||||
| Background: Nails are considered epidermal appendages, and as such, are commonly affected in patients with psoriasis, 80% of whom are likely to develop nail psoriasis as a result of their condition. Nail involvement is highly prevalent in the psoriasis population, can serve as a poor prognostic factor of disease, and greatly affects the QoL of patients with psoriasis. Multiple topical and systemic medications have been studied for this condition. Aim: This study aimed to discuss the various therapies, including topicals, injectables, systemic, lasers, and complementary therapies that have been explored for the treatment of nail psoriasis. Methods: A literature search was conducted in PubMed and Embase in October 2022 using a combination of the terms ‘nail’ AND ‘psoriasis.’ Our initial search was filtered using the “clinical trial” filter in the PubMed and Embase search options. Only studies written in the English language were reviewed. All original prospective, retrospective studies and non-experimental descriptive studies were chosen for the purpose of this review. Conclusion: We concluded that triamcinolone acetonide & botulinium toxin type A are effective in treating nail psoriasis symptoms like pitting, leukonychia, onychorrhexis, subungual hyperkeratosis, & onycholysis. As a result, both may be better options for nail psoriasis patients who have both nail matrix & nail bed involvement. | ||||
|
Statistics Article View: 316 PDF Download: 400 |
||||
